Trials / NCT01482195
Trial of Subretinal Injection of (rAAV2-VMD2-hMERTK)
Completed Phase 1 Gene therapy
- Sponsor
- King Khaled Eye Specialist Hospital
- Treatment
- Subretinal administration of rAAV2-VMD2-hMERTKRecombinant Adeno-Associated Virus
- Gene
- MERTK
- Conditions
- Retinal Disease, Retinitis Pigmentosa
- Ages
- 14 Years to 70 Years
- Enrollment
- 6 participants
- Started
- 2011-08
- Main results expected
- 2013-08
- Results posted
- Yes
- Record last updated
- 2022-01-26
What the study is testing
This study was to assess the safety of gene transfer via subretinal administration of rAAV2-VMD2-hMERTK in subjects with MERTK-associated retinitis pigmentosa (RP).
Where it runs
Saudi Arabia (1)
- King Khaled Eye Specialist Hospital, Riyadh